Suboptimal dosing of rituximab in male and female patients with DLBCL
- 30 January 2014
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 123 (5) , 640-646
Abstract
To determine the effect of gender on outcome, the male hazard ratio for progression-free survival (HRPFS-male) was determined in patients with diffuse large B-cell lymphoma (DLBCL). In young patients (MapThera International Trial study), HRPFS-male was 1.3 (P = .092) without and 1.1 (P = .660) with rituximab. In elderly patients (RICOVER-60 study), HRPFS-male was 1.1 (P = .348) with CHOP but increased to 1.6 (P = .004) with R-CHOP. The similar improvements of outcome in young patients were associated with similar rituximab clearances in young males and females (9.89 vs 10.38 mL/h; P = .238), whereas the greater benefit for elderly females was associated with a slower rituximab clearance (8.47 vs 10.59 mL/h; P = .005) and hence higher serum levels and longer exposure times, attributable to an age-dependent (P = .004) decrease of rituximab clearance in females but not males. Compared with elderly females, all other subgroups had significantly faster rituximab clearances and hence appear to be suboptimally dosed when rituximab is given at 375 mg/m2. Although early results of pharmacokinetic-based prospective trials designed to exploit the full therapeutic potential of rituximab suggest that increased doses and/or prolonged exposure times can improve the outcome of elderly males with DLBCL, further studies are warranted that address the optimization of rituximab dose and schedule in all subgroups of DLBCL patients.Keywords
This publication has 27 references indexed in Scilit:
- The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLBlood, 2012
- The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplaseBritish Journal of Clinical Pharmacology, 2011
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2011
- Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopeniaAnnals of Oncology, 2011
- Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*European Journal of Haematology, 2010
- Forging a field: the golden age of iron biologyBlood, 2008
- Pharmacokinetics of rituximab and its clinical use: Thought for the best use?Critical Reviews in Oncology/Hematology, 2007
- The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based studyLeukemia & Lymphoma, 2007
- Prognostic Factors in Diffuse Large Bcell Lymphoma Treated by Riskadopted TherapyInternal Medicine, 2006
- Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variablesCancer, 1990